Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of BRAF V600E-driven non-small cell lung cancer (NSCLC) with our guest Dr. Gregory Riely, a thoracic medical oncologist from Memorial Sloan Kettering Cancer Center.

Join us as we explore:

Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't miss it!

Listen us on:

Follow us on social media:

#BRAFV600E, #NSCLC, #BRAFMEKinhibitor, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists.

Key topics included:

Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!

#MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib.

Key topics include:

The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting.

Listen us on:

Follow us on social media:

Don’t forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights!

#LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting.

We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including:

With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes.

Listen us on:

Follow us on social media:

Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below!

#LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings.

We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions.

Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors.

Key topics covered in this episode:

Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology.

Listen us on:

Follow us on social media:

Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care!

#MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain dive deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with curative intent. Joined by leading thoracic medical oncologist Dr. Sanjay Popat from London, they discussed the critical role of next-generation sequencing (NGS) in treatment planning, the importance of proper staging, and the implications of actionable mutations.

Key topics covered included:

Join us for an informative discussion that unpacks the latest advancements in NSCLC treatment and emphasizes the importance of personalized care.

Listen us on:

Follow us on social media:

Don't forget to subscribe for more episodes in our treatment algorithm series!

#EarlyStageNSCLC, #CHECKMATE816, #NeoadjuvantTherapy, #PrecisionMedicine, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC).

We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included:

Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!

#SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers

Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer.

Episode Highlights:

Join us as we explore these critical topics and provide valuable insights for healthcare professionals managing colorectal cancer treatments.

Listen us on:

Follow us on social media:

Don't forget to subscribe for more episodes!

#ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment.

Join us as we discussed:

This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest!

Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls.

Listen us on:

Follow us on social media:

Subscribe to our channel for more oncology insights and updates!

This discussion was in support of an independent educational grant provided by Pfizer

In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings.

Key topics discussed included:

Join us for this comprehensive discussion on colorectal cancer management in 2026.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers